Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NovoPen™ 4 | Device | |||
| NovoPen® 3 | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of overall pen preference | after 12 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c | ||
| Adverse device effects | ||
| Adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Vienna | 1090 | Austria | |||
| Novo Nordisk Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | Kolaczynski M, Chayer D. NovoPen® 4: perceived as superior in handling and acceptance versus HumaPen® Ergo and OptiPen® Pro in patients and healthcare professionals. Diabetes Technology & Therapeutics 2005; 7 (2): 390 | ||
| Result | Goke B, Gamba S, Erdtsieck RJ, Gilbey S, Schober E, Lytzen L, Kolaczynski M. NovoPen 4 offers superior performance, handling and acceptance compared with NovoPen 3 in insulin-treated diabetes patients. Diabetes Technology and Therapeutics 2005; 7 (2): 379-380 |
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vienna |
| A 1090 |
| Austria |
| Novo Nordisk Investigational Site | Cologne | 50858 | Germany |
| Novo Nordisk Investigational Site | Leverkusen | 51373 | Germany |
| Novo Nordisk Investigational Site | München | 81377 | Germany |
| Novo Nordisk Investigational Site | Saint Ingbert | 66386 | Germany |
| Novo Nordisk Investigational Site | Speyer | 67346 | Germany |
| Novo Nordisk Investigational Site | Völklingen | 66333 | Germany |
| Novo Nordisk Investigational Site | Catania | 95122 | Italy |
| Novo Nordisk Investigational Site | Palermo | 90127 | Italy |
| Novo Nordisk Investigational Site | Parma | 43100 | Italy |
| Novo Nordisk Investigational Site | Roma | 00165 | Italy |
| Novo Nordisk Investigational Site | Torino | 10144 | Italy |
| Novo Nordisk Investigational Site | Almere Stad | 1315 RA | Netherlands |
| Novo Nordisk Investigational Site | Amsterdam | 1081 HV | Netherlands |
| Novo Nordisk Investigational Site | Heerlen | 6419 PC | Netherlands |
| Novo Nordisk Investigational Site | Rotterdam | 3015 GD | Netherlands |
| Novo Nordisk Investigational Site | The Hague | 2512 VA | Netherlands |
| Novo Nordisk Investigational Site | Veldhoven | 5504 DB | Netherlands |
| Novo Nordisk Investigational Site | Belfast | BT12 6BE | United Kingdom |
| Novo Nordisk Investigational Site | Belfast | BT37 9RH | United Kingdom |
| Novo Nordisk Investigational Site | Leeds | LS9 7TF | United Kingdom |
| Novo Nordisk Investigational Site | Sidcup | DA14 6LT | United Kingdom |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003922 | Diabetes Mellitus, Type 1 |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided